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eft Ventricular
ypertrophy and Excess
ardiovascular Mortality
s Late Gadolinium
nhancement the Imaging Link?*
ichael L. Chuang, MD,*
arren J. Manning, MD, FACC*†
oston, Massachusetts
eft ventricular hypertrophy (LVH) is well established as a
redictor of excess cardiovascular morbidity and mortality.
nitial studies demonstrated an association between electro-
ardiographic LVH and likelihood of adverse events, but at
cceptable levels of specificity, the sensitivity of the electro-
ardiogram for LVH is low. Subsequently, M-mode echo-
ardiographically determined LVH was shown to predict
ardiovascular morbidity and mortality independent of clin-
cal risk factors including age, sex, smoking, and diabetes
1). The additional risk associated with LVH has been
ttributed to factors such as subendocardial ischemia related
o perfusion gradient or increased arrhythmogenicity due in
art to changes in myocardial substrate, but noninvasive in
ivo methods for characterizing myocardial composition are
either widely available nor commonly used in the clinical
etting.
See page 284
Although not currently approved by the Food and Drug
dministration (FDA) for imaging of the heart, gadolinium
helates are widely used in cardiovascular magnetic reso-
ance (CMR) as T1-shortening contrast agents. Work in
he mid-1980s, with a canine coronary-ligation model,
emonstrated that irreversibly injured myocardium exhibits
ignificantly shortened T1 as compared with normal myo-
ardium when imaged 5 min after intravenous injection of
igh-dose (0.5 mmol/kg) gadolinium (2,3). These and
imilar early studies were limited by the relatively low image
ontrast (typically 50%) between normal and irreversibly
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.o
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srael Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.njured myocardium achieved with spin-echo CMR imag-
ng. Subsequent work with inversion-recovery segmented
radient echo CMR methods were able to achieve signal
ntensity differences of up to 500% between normal and
nfarcted myocardium (4,5), where normal myocardium is
ark and infarcted myocardium is enhanced (bright). The
undamental technique is straightforward: intravenous in-
ection of gadolinium contrast followed by inversion recov-
ry imaging after a 10- to 15-min delay. This is known in
he CMR world as late gadolinium enhancement (LGE),
elayed enhancement, delayed hyperenhancement, or de-
ayed contrast enhancement.
With inversion-recovery segmented gradient echo meth-
ds, comparison with necropsy in animals demonstrated
hat LGE is able to identify and accurately localize even very
mall infarcts (4). Both animal and human studies showed
hat LGE is able to identify both acute and chronic
ermanent myocardial injury and differentiates between
rreversibly injured and stunned or hibernating myocardium.
urther, LGE imaging has excellent agreement with
ositron emission tomography for determination of extent
f myocardial scar (6) and is superior to single photon
mission-computed tomography for identifying small in-
arcts, due to the enhanced spatial resolution of CMR
ethods (7). Landmark studies by Kim et al. (8) and others
9,10) showed that extent and transmurality of LGE was
redictive of recovery of function after mechanical revascu-
arization. Whereas initial data suggested that LGE was
pecific for irreversible ischemic injury (4), subsequent
tudies showed that LGE was associated with a multiplicity
f conditions, including hypertrophic cardiomyopathy
HCM) (11,12), myocarditis (13), nonischemic dilated
ardiomyopathy (14), cardiac sarcoidosis (15), cardiac amy-
oidosis (16), Anderson-Fabry disease (17), and pulmonary
rterial hypertension (AH) (18). Specific conditions are
ssociated with characteristic patterns of LGE. For exam-
le, LGE in HCM commonly occurs in the interventricular
eptum at the right ventricular insertion points, whereas
GE in myocardial infarction has a subendocardial or
ransmural distribution.
Our present understanding of the mechanism of LGE is
hat it represents a relative paucity of viable myocytes. In the
ealthy state, the majority (approximately 75%) of myocar-
ial tissue volume is occupied by normal myocytes (19),
hich do not allow gadolinium chelates to cross their intact
arcolemmal membranes. Acute necrosis allows gadolinium
o diffuse across damaged membranes, whereas scar is
haracterized by increased extracellular matrix that can host
adolinium; in either case, the tissue concentration of
adolinium is increased relative to viable myocardium,
eading to shorter T1 and bright signal on CMR imaging.
Hypertrophic cardiomyopathy is strongly associated with
GE (11,12), but LVH associated with aortic stenosis (AS)
ight also result in positive LGE scans (20,21). In this issuef the Journal, Rudolph et al. (22) extend our knowledge of
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January 20, 2009:292–4 CMR LGE and Arterial Hypertensionhe range of conditions associated with LGE. They com-
ared LGE findings in patients with HCM and AS with
atients with LVH secondary to AH, a condition not
reviously associated with LGE. To their credit, subjects
40 years of age had coronary artery disease rigorously
xcluded by coronary angiography, whereas younger subjects
ere all free of clinical risk factors. Consistent with prior
tudies, LGE was very common (72%) among HCM
ubjects and most commonly located at the right ventricular
ree-wall insertion points. The presence and extent of LGE
ere significantly associated with increasing left ventricular
LV) mass index. Among those with AS, 62% displayed
GE in a patchy, noncoronary distribution that was asso-
iated with increasing LV mass index. Most provocative are
he findings that 50% of AH subjects with LVH exhibited
GE with a trend toward greater LV mass index among
H subjects with LGE. Like AS, the LGE pattern was
atchy, predominantly nonsubendocardial, and averaged 5%
f LV mass.
The study of Rudolph et al. (22) adds prolonged AH with
VH to the range of conditions associated with cardiac
GE and is broadly in accord with a contemporaneous
ublication by Andersen et al. (23). Just as preliminary work
uggests LGE in HCM might be a predictor of sudden
eath (14) or ventricular arrhythmias (24), perhaps LGE in
he AH with LVH population will prove to be the imaging
ink to increased cardiovascular risk in this population.
wong et al. (25) have shown that, among a variety of
atients without known prior myocardial infarction, the
resence of any LGE was a significant predictor of cardio-
ascular morbidity and mortality even after accounting for
jection fraction, resting wall-motion abnormalities, and
ngiographic coronary artery disease.
However, before we can advocate CMR for the large
opulation of patients with AH and LVH, considerable
ork needs to be done. A majority of subjects with LVH by
chocardiography did not have CMR LVH and were
xcluded from the Rudolph et al. (22) study, but their
hresholds for LVH are greater than other published values
26) and might represent an extreme. What is the optimal
patial resolution for LGE imaging in patients with AH and
VH? What signal intensity difference constitutes LGE?
nd most importantly, in this population, does LGE
rovide independent incremental prognostic value to justify
he expense of CMR and potential risk of gadolinium
xposure? It seems that the next steps include confirmation
f the prevalence of LGE among patients with AH and
stablishing whether LGE has independent prognostic
alue with respect to cardiovascular morbidity and mortality.
eprint requests and correspondence: Dr. Warren J. Manning,
ardiovascular Division, Beth Israel Deaconess Medical Center,
30 Brookline Avenue, Boston, Massachusetts 02215. E-mail:
manning@bidmc.harvard.edu.EFERENCES
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